<DOC>
	<DOCNO>NCT01957657</DOCNO>
	<brief_summary>The objective trial investigate effect different degree renal impairment pharmacokinetics safety combination BI 207127 faldaprevir 3 day dose ( BI 207127 bid , faldaprevir qd ) single dose BI 207127 faldaprevir day 4 .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Combination BI 207127 Faldaprevir Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criterion : Healthy volunteer ( male female ) patient impaired renal function ( estimate glomerular filtration rate ( eGFR ) 89 15 ) relatively good health determine past medical history , physical examination , vital sign , ECG laboratory assessment ( aside abnormality specific renal impairment ) Age 18 79 year Subjects must able understand comply study requirement Exclusion criterion : Any relevant deviation healthy condition healthy volunteer Subjects significant disease renal impairment exclude . A significant disease define disease opinion investigator : put patient risk participation study may influence result study may influence patient ability participate study stable condition Diabetic hypertensive patient enter trial disease significant accord criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>